#ReaganUdallFoundation
LightNews LightNews
rarediseaseadvisor.bsky.social
What is Expanded Access? 💊

For patients facing serious or life-threatening conditions who have run out of options and do not qualify for a clinical trial, Expanded Access may offer another path forward.

Learn more: https://bit.ly/4bS02Wu

#RareAdvocacySpotlight #ReaganUdallFoundation
The image is a graphic about "Expanded Access" by the Reagan-Udall Foundation for the FDA. It includes the text: "Expanded Access (EA), also called compassionate use, named-patient use, or single-patient access, helps patients with serious or life-threatening conditions access investigational treatments not yet approved by the FDA." There is also an illustration of two hands clasped together, suggesting support or partnership. At the bottom, there is a label: "Rare Advocacy Spotlight." The image features informational text on Expanded Access (EA) by the Reagan-Udall Foundation for the FDA. It describes EA as a program for patients with no other approved treatment options, stating that physicians, caregivers, and healthcare teams can request it. The background includes a person with hands on their head, partially obscured. The bottom section displays a blue stripe with the text "Rare Advocacy Spotlight." A promotional image for the Reagan-Udall Foundation for the FDA. It features a person embracing another person above text reading "EA Provides Step-By-Step Guidance." Bullet points highlight support for patients, caregivers, healthcare providers, companies, and sponsors. The bottom section includes a "Rare Advocacy Spotlight" logo. The background is a gradient of yellow transitioning to blue.
February 12, 2026 at 8:07 PM
rarediseaseadvisor.bsky.social
💬 Notable Quotes from the Reagan-Udall Foundation for the FDA

🔍Learn more about the Reagan-Udall Foundation and its programs, including Expanded Access: https://reaganudall.org/rare-disease

#RareAdvocacySpotlight #ReaganUdallFoundation #RareDisease
An image with a purple background featuring the logo of the Reagan-Udall Foundation for the FDA at the top. Below the logo, there is a large quote symbol and the words "Notable Quotes" in white text. At the bottom, there is a banner with the text "Rare Advocacy Spotlight" and a graphic of a megaphone. The image is a graphic for the Reagan-Udall Foundation for the FDA. It features a quote about stakeholder engagement in therapy development. The lower section has a headshot of Susan C. Winckler, CEO of the foundation, with her name and title. A logo and text reading "Rare Advocacy Spotlight" are at the bottom. The colors are predominantly purple and blue. The image features a quote about the importance of expanded access to investigational medicines for people with rare diseases. The text mentions its critical value when few treatments exist. Below the quote, there is a photo of Lea Ann Browning-McNee, listed as the Director of Communication and Stakeholder Engagement at the Reagan-Udall Foundation for the FDA. The lower section displays the "Rare Advocacy Spotlight" with a stylized logo.
February 12, 2026 at 7:17 PM